CD274 and urinary bladder carcinoma: A phase Ib study (NCT02891161) demonstrated the safety of combining the anti-PD-L1 checkpoint inhibitor durvalumab with radiation therapy to the bladder (64.8 Gy in 36 fractions) in 6 patients with locally advanced bladder cancer, with no patients experienced dose limiting toxicity (68).